Pazoo Inc (OTCMKTS:PZOO) recorded a trade volume of 52.84 million, during the February 15 trading session, but failed to record a change in its share value. The stock closed at a share price of $0.0004 and has observed a series of rapid ups and downs, during the past 1-week. The main reason behind the stock’s unimpressive performance is its lack of news and updates. Pazoo has a history of being irregular with its updates and filings. Moreover, the company is yet to files its financial results for the 4Q2016.
The last press release from PZOO revealed that its subsidiary, MA & Associates LLC, has received approval from the Las Vegas City Council and a license to operate a medical marijuana testing lab, in the region. The company noted that this was the final regulatory hurdle, in its efforts to begin operations. The lab itself has been fully operational for some time, but a regulatory approval was needed to legally start accepting test samples. Moreover, Pazoo announced that it would be hiring several key employees for the new facility and would start marketing its services, to start receiving samples immediately.
Although this announcement was made over a month ago, there has been no update from the company on the hiring of key figures or the progress the new facility has made thus far. The CEO of PZOO, David Cunec, expressed his pleasure at obtaining the license and thanked the company’s shareholders and investors, for their patience and constant support. He pointed out that there were many hurdles faced by the company, in obtaining the license, but now they are ready to serve the cannabis market in Nevada.
It should be noted here that Mr. Cunec is also a member of the newly formed New Jersey Cannabusiness Association. The new body is responsible for the promotion and guidance of Garden State Businesses, through the legal and regulatory requirements, enforced by the state’s marijuana laws. Eventually, the association plans to get recreational cannabis legalized in the Garden State.
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells